Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
PLX
$3
$
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.
Beta
-0.222
Average Volume
Market Cap
Last Dividend
CIK
0001006281
ISIN
US74365A3095
CUSIP
74365A309
CEO
Dror Bashan
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
213
IPO Date
1998-05-15
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Reviewing Protalix BioTherapeutics (NYSE:PLX) & JATT Acquisition (NYSE:JATT) | Protalix BioTherapeutics (NYSE: PLX - Get Free Report) and JATT Acquisition (NYSE: JATT - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends and analyst recommendations. Insider and Institutional Ownership 16.5% of Protalix | Defense World | 2026-02-05 01:50:49 |
| Polaryx to Present Late-Breaker Data Related to SOTERIA at the 22nd Annual WORLDSymposium™ as Company Prepares for SOTERIA Trial Launch | Oral presentation provides additional scientific rationale on Krabbe disease, one of four LSDs in the Phase 2 SOTERIA basket trial designed to evaluate the safety and clinical activity of lead drug candidate PLX-200 Oral presentation provides additional scientific rationale on Krabbe disease, one of four LSDs in the Phase 2 SOTERIA basket trial designed to evaluate the safety and clinical activity of lead drug candidate PLX-200 | GlobeNewsWire | 2026-02-03 08:30:00 |
| A March Decision That Could Change Protalix BioTherapeutics Outlook | Protalix Bio Therapeutics (PLX) received a positive CHMP opinion for Elfabrio's every-four-weeks dosing in stable adult Fabry patients, pending EC approval by March. PLX's Elfabrio could halve infusion frequency, improving patient quality of life and potentially strengthening its competitive position in the Fabry market. Elfabrio drove over half of PLX's FY24 product revenue, with sales rising and a potential $25 million milestone tied to EU approval. | Seeking Alpha | 2026-02-01 21:27:08 |
| Protalix wins EU panel backing for expanded dosing of Fabry disease drug | Protalix Biotherapeutics Inc (NYSE-A:PLX, FRA:PBDA) said on Friday that the European Medicines Agency's human medicines committee has issued a positive opinion recommending approval of an expanded dosing regimen for Elfabrio, its treatment for Fabry disease, in adult patients. The Committee for Medicinal Products for Human Use (CHMP) recommended approval of a 2 mg/kg every-four-weeks dosing schedule for Elfabrio in adult Fabry patients who are stable on enzyme replacement therapy, following a re-examination of the application. | Proactive Investors | 2026-01-30 10:20:41 |
| Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU | Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion following re-examination, which will be reviewed by the European Commission (EC), with a decision anticipated by March 2026 | GlobeNewsWire | 2026-01-30 09:47:00 |
| Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU | Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion following re-examination, which will be reviewed by the European Commission (EC), with a decision anticipated by March 2026 | GlobeNewsWire | 2026-01-30 09:47:00 |
| Nasdaq leads losses as investors juggle earnings, Fed Chair nomination | 12:00pm: Apple faces challenges ahead Analysts view Apple’s near-term growth as strong, led by iPhone and Services, but longer-term margin sustainability... | Proactive Investors - Finance | 2026-01-30 07:04:00 |
| Protalix wins EU panel backing for expanded dosing of Fabry disease drug | Protalix Biotherapeutics Inc (NYSE-A:PLX, FRA:PBDA) said on Friday that the European Medicines Agency’s human medicines committee has issued a positive... | Proactive Investors - Finance | 2026-01-30 05:19:00 |
| Protalix BioTherapeutics CEO outlines 2026 priorities, highlights progress across clinical pipeline | Protalix Biotherapeutics Inc (NYSE-A:PLX) on Monday shared an update from its CEO Dror Bashan, who highlighted the company's strategic priorities for 2026, with a focus on advancing its clinical pipeline while building on its partnered commercial base. In a letter to stockholders, Bashan wrote that Protalix remains focused on “building with our partners a growing, profitable business and an innovative pipeline for patients with high-need rare diseases. | Proactive Investors | 2026-01-05 08:41:57 |
| Protalix BioTherapeutics Letter to Stockholders | CARMIEL, Israel, Jan. 5, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today announced the following update from President and Chief Executive Officer, Dror Bashan, to its stockholders. Dear Protalix Stockholders, As we look forward to 2026, we remain focused on building with our partners a growing, profitable business and an innovative pipeline for patients with high-need rare diseases. | PRNewsWire | 2026-01-05 06:50:00 |
| Micron shares jump after strong Q1 earnings, robust outlook | Micron Technology Inc (NASDAQ:MU) on Wednesday posted stronger-than-expected fiscal first-quarter results and forecast robust growth for the next quarter,... | Proactive Investors - Finance | 2025-12-17 11:31:00 |
| Protalix BioTherapeutics partners with Secarna Pharmaceuticals on rare kidney disease drug development | Protalix Biotherapeutics Inc (NYSE-A:PLX) announced that it has entered into a collaboration and option agreement with Secarna Pharmaceuticals to jointly develop new antisense oligonucleotide (ASO) therapies targeting rare kidney diseases, the companies said Tuesday. Secarna, headquartered in Martinsried, Germany, specializes in the discovery and development of oligonucleotide-based therapeutics. | Proactive Investors | 2025-12-17 08:41:56 |
| Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement | Partnership combines Protalix's rare disease and biologics expertise with Secarna's AI–powered OligoCreator® platform to jointly develop pharmaceutical candidates for rare renal indications Protalix is granted an exclusive option to license any active compounds derived from the research for potential clinical development and commercialization CARMIEL, Israel and MARTINSRIED, Germany , Dec. 17, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases with significant unmet needs, and Secarna Pharmaceuticals GmbH & Co. KG, a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, today announced that they have entered into a collaboration and option agreement. Under this agreement, the companies have agreed to partner in the discovery of novel antisense oligonucleotide (ASO) therapies against multiple targets for rare renal indications. | PRNewsWire | 2025-12-17 06:50:00 |
| Oracle shares slide as $10B Michigan data center faces funding uncertainty | Oracle Corp (NYSE:ORCL, XETRA:ORC) shares fell almost 6% on Wednesday morning after the Financial Times reported that its plans for a $10 billion data... | Proactive Investors - Finance | 2025-12-17 06:03:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 8-K | 2026-02-11 | 2026-02-11 | View Filing |
| 8-K | 2026-01-30 | 2026-01-30 | View Filing |
| 8-K | 2026-01-05 | 2026-01-05 | View Filing |
| 4 | 2025-12-23 | 2025-12-23 | View Filing |
| 4 | 2025-11-19 | 2025-11-19 | View Filing |
| 10-Q | 2025-11-13 | 2025-11-13 | View Filing |
| 8-K | 2025-11-13 | 2025-11-13 | View Filing |
| 8-K | 2025-11-03 | 2025-11-03 | View Filing |
| 8-K | 2025-10-17 | 2025-10-17 | View Filing |
| 4 | 2025-09-04 | 2025-09-04 | View Filing |
| 4 | 2025-09-04 | 2025-09-04 | View Filing |
| 4 | 2025-09-04 | 2025-09-04 | View Filing |
| 4 | 2025-09-04 | 2025-09-04 | View Filing |
| 4 | 2025-09-04 | 2025-09-04 | View Filing |
| 4 | 2025-09-04 | 2025-09-04 | View Filing |
| 4 | 2025-09-04 | 2025-09-04 | View Filing |
| 4 | 2025-09-04 | 2025-09-04 | View Filing |
| 4 | 2025-09-04 | 2025-09-04 | View Filing |
| 3 | 2025-08-25 | 2025-08-25 | View Filing |
| EFFECT | 2025-08-25 | 2025-08-25 | View Filing |
| 8-K | 2025-08-22 | 2025-08-22 | View Filing |
| 424B5 | 2025-08-22 | 2025-08-22 | View Filing |
| S-3/A | 2025-08-14 | 2025-08-14 | View Filing |
| 10-Q | 2025-08-14 | 2025-08-14 | View Filing |
| 8-K | 2025-08-14 | 2025-08-14 | View Filing |
| 4 | 2025-08-12 | 2025-08-12 | View Filing |
| 8-K | 2025-08-01 | 2025-08-01 | View Filing |
| 8-K | 2025-07-21 | 2025-07-21 | View Filing |
| 3 | 2025-07-03 | 2025-07-03 | View Filing |
| 8-K | 2025-06-26 | 2025-06-26 | View Filing |
| 10-Q | 2025-05-09 | 2025-05-09 | View Filing |
| 8-K | 2025-05-09 | 2025-05-09 | View Filing |
| ARS | 2025-05-08 | 2025-05-08 | View Filing |
| DEF 14A | 2025-04-30 | 2025-04-30 | View Filing |
| S-3 | 2025-04-28 | 2025-04-28 | View Filing |
| 8-K | 2025-04-23 | 2025-04-23 | View Filing |
| 8-K | 2025-03-17 | 2025-03-17 | View Filing |
| 424B5 | 2025-03-17 | 2025-03-17 | View Filing |
| 10-K | 2025-03-17 | 2025-03-17 | View Filing |
| 8-K | 2025-03-17 | 2025-03-17 | View Filing |
| 8-K | 2024-12-31 | 2024-12-31 | View Filing |
| 8-K | 2024-12-23 | 2024-12-23 | View Filing |
| 10-Q | 2024-11-14 | 2024-11-14 | View Filing |
| 8-K | 2024-11-14 | 2024-11-14 | View Filing |
| 4/A | 2024-11-05 | 2024-11-05 | View Filing |
| SC 13G/A | 2024-10-25 | 2024-10-25 | View Filing |
| 8-K | 2024-10-25 | 2024-10-25 | View Filing |
| 4 | 2024-09-24 | 2024-09-24 | View Filing |
| 4 | 2024-09-24 | 2024-09-24 | View Filing |
| 10-Q | 2024-08-14 | 2024-08-14 | View Filing |
| 8-K | 2024-08-14 | 2024-08-14 | View Filing |
| S-8 | 2024-07-01 | 2024-07-01 | View Filing |
| 8-K | 2024-06-28 | 2024-06-27 | View Filing |
| ARS | 2024-05-17 | 2024-05-17 | View Filing |
| DEFA14A | 2024-05-17 | 2024-05-17 | View Filing |
| 10-Q | 2024-05-10 | 2024-05-10 | View Filing |
| 8-K | 2024-05-10 | 2024-05-10 | View Filing |
| DEF 14A | 2024-04-29 | 2024-04-29 | View Filing |
| 4 | 2024-04-03 | 2024-04-03 | View Filing |
| 10-K | 2024-03-14 | 2024-03-14 | View Filing |
| 8-K | 2024-03-14 | 2024-03-14 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|